THE CLINICAL EFFECTIVENESS OF ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW

Abstract

Lung cancer presents a significant epidemiological and economic burden worldwide. This deadly type of cancer ranks second in incidence and first in mortality among all cancers. The rapid increase in new and expensive treatment options places a substantial financial strain on public healthcare systems. Given the limited healthcare resources, the economic evaluation of new cancer drugs is crucial for ensuring the sustainability of healthcare systems and improving patients' access to treatments. This study aims to systematically review health state utility values (HSUVs) associated with traditional chemotherapy and targeted therapies in the first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). A search was conducted in PubMed, EMBASE, and BioMed databases to identify publications reporting HSUVs, and 10 studies were selected from 1319 based on predefined criteria. The study found that HSUVs for targeted therapies were consistently higher across all health states compared to traditional chemotherapy. The included publications provide a comprehensive framework of HSUVs applicable to this disease and highlight the need for more empirical research to obtain a broader range of HSUVs for NSCLC.

Keywords

• non-small cell lung cancer
• cost-utility analysis
• health state utility values
• health-related quality of life
• chemotherapy